Trial · NCT00350870

CBT With Disulfiram and Contingency Management

NCT00350870, Phase 1, Completed, Yale University; results first posted 2014-12-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. CBT With Disulfiram and Contingency Management. Trials, record NCT00350870. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00350870

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: CBT With Disulfiram and Contingency Management
NCT number: NCT00350870
Status: Completed
Phases: Phase 1
Enrollment: 181 participants, actual
Lead sponsor: Yale University
Conditions: Cocaine Abuse
Interventions: disulfiram, Placebo, Placebo plus Contingency Management, Disulfiram plus Contingency Management
First posted: 2006-07-11
Last updated: 2014-12-03
Results first posted: 2014-12-03

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Cocaine Use by Self Report	12 weeks	Self-reports of substance use will be documented at each contact via the Substance Use Calendar. Similar to the Form-90 and the Time Line Follow-Back, which have been shown to be reliable and valid instruments for monitoring substance use and other outcomes in longitudinal studies202-204, the Substance Use Calendar allows a flexible, continuous evaluation of substance use on a daily basis.
Primary	Change in Cocaine Use by Urine Toxicology Results	12 weeks	We will use the Roche onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepenes, and opioids.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Cocaine Use by Self Report	12 weeks		percentage of days abstinent	MEAN
PRIMARY	Change in Cocaine Use by Urine Toxicology Results	12 weeks		percentage of negative urines	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Cocaine Use by Self Report	Placebo	72.2	Standard Deviation 27.3	percentage of days abstinent
Change in Cocaine Use by Self Report	Disulfiram	79.2	Standard Deviation 18.1	percentage of days abstinent
Change in Cocaine Use by Self Report	Placebo Plus Contingency Management	91.1	Standard Deviation 13.6	percentage of days abstinent
Change in Cocaine Use by Self Report	Disulfiram Plus Contingency Management	69.6	Standard Deviation 31.7	percentage of days abstinent
Change in Cocaine Use by Urine Toxicology Results	Placebo	17.9	Standard Deviation 32.3	percentage of negative urines
Change in Cocaine Use by Urine Toxicology Results	Disulfiram	30.1	Standard Deviation 39.6	percentage of negative urines
Change in Cocaine Use by Urine Toxicology Results	Placebo Plus Contingency Management	53	Standard Deviation 41	percentage of negative urines
Change in Cocaine Use by Urine Toxicology Results	Disulfiram Plus Contingency Management	42.6	Standard Deviation 43.7	percentage of negative urines

Source ClinicalTrials.gov

Participant flow16

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	27
Overall Study	STARTED	Disulfiram	28
Overall Study	STARTED	Placebo Plus Contingency Management	22
Overall Study	STARTED	Disulfiram Plus Contingency Management	22
Overall Study	Had at Least 1 Day of Med	Placebo	19
Overall Study	Had at Least 1 Day of Med	Disulfiram	24
Overall Study	Had at Least 1 Day of Med	Placebo Plus Contingency Management	18
Overall Study	Had at Least 1 Day of Med	Disulfiram Plus Contingency Management	19
Overall Study	COMPLETED	Placebo	5
Overall Study	COMPLETED	Disulfiram	11

1 to 10 of 16Source ClinicalTrials.gov

See all 16 participant flow

Adverse events56

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Drowsiness	General disorders	Placebo	2	27	2
other	Drowsiness	General disorders	Disulfiram	5	28	5
other	Drowsiness	General disorders	Placebo Plus Contingency Management	2	22	2
other	Drowsiness	General disorders	Disulfiram Plus Contingency Management	2	22	2
other	Fatigue	General disorders	Placebo	1	27	1
other	Fatigue	General disorders	Disulfiram	3	28	3
other	Fatigue	General disorders	Placebo Plus Contingency Management	2	22	2
other	Fatigue	General disorders	Disulfiram Plus Contingency Management	3	22	3
other	Restlessness	General disorders	Placebo	2	27	2
other	Restlessness	General disorders	Disulfiram	4	28	4

1 to 10 of 56Source ClinicalTrials.gov

See all 56 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Disulfiram
Total, all-cause mortality	Placebo Plus Contingency Management
Total, all-cause mortality	Disulfiram Plus Contingency Management
Total, other adverse events	Placebo	12	27
Total, other adverse events	Disulfiram	17	28
Total, other adverse events	Placebo Plus Contingency Management	10	22
Total, other adverse events	Disulfiram Plus Contingency Management	17	22
Total, serious adverse events	Placebo	10	27
Total, serious adverse events	Disulfiram	10	28

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
22695473	DERIVED	PubMed
22775772	DERIVED	PubMed
42423707	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01DA019078	Maximizing CBT's Efficacy with Medication & CM	CARROLL, KATHLEEN M.	YALE UNIVERSITY	NATIONAL INSTITUTE ON DRUG ABUSE	2005 to 2009

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00350870

GET https://conductscience.org/api/trials/v1/NCT00350870/events?page=2

API reference For AI assistants